Donate For Public and Patients Store Search

S041 - Skinternal Medicine: An Update on Cutaneous Manifestations of Systemic Disease

Sunday, March 3; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Diagnose skin diseases that are associated with internal manifestations more effectively
  • Develop an appropriate, yet cost effective, method of evaluating patients with complex medical/dermatological problems
  • Formulate an evidence-based management for patients with complex medical/dermatological problems

Description

The session is a case-based discussion of complex dermatological problems that have systemic implications. We will utilize an Audience Response System for this session and therefore, Handouts WILL NOT be provided prior to the session. Speakers will be asked to upload a handout following their presentation. This Activity has been approved by the American Board of Dermatology (ABD) for up to 30 Component 2 Self-Assessment credits.

Disclosures

  • Callen, Jeffrey Phillip, MD: 3M Pharmaceuticals – SH(ST); Abbott Laboratories – SH(ST); AbbVie – SH(ST); Allergan, Inc – SH(ST); Celgene – SH(ST); Johnson and Johnson – SH(ST); Merck & Co., Inc – SH(ST); Pfizer Inc. – SH(ST); Principia Biopharma Inc – Data Safety Monitoring Board(H); Procter & Gamble Company – SH(ST); UpToDate, Inc. – B(H);
  • Fett, Nicole, MD: La Roche-Posay Laboratorie Pharmaceutique – I(Fees); Pfizer Inc. – I(Fees);
  • Gudjonsson, Johann E., MD: AbbVie – I(Grants/Research Funding); Genentech, Inc. – I(Grants/Research Funding); miRagen Therapeutics, Inc. – C(H); Novartis – A(H); Sun Pharmaceutical Industries Ltd. – I(Grants/Research Funding);
  • Kirsner, Robert S., MD, PhD: AbbVie – C(Grants/Research Funding); Kerecis Limited – A(H); Molynecke – A(H); National Healing Corp – A(H); Pfizer Inc. – A(H);
  • Maderal, Andrea, MD: no financial relationships exist with commercial interests.
  • Micheletti, Robert, MD: no financial relationships exist with commercial interests.
  • Owen, Cindy, MD: AbbVie – I(Grants/Research Funding); Accuitis, Inc – I(Grants/Research Funding); Aclaris Therapeutics Inc. – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Bristol-Myers Squibb – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Galderma USA – I(Grants/Research Funding); Janssen Pharmaceuticals, Inc – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Sol-Gel Technologies – I(Grants/Research Funding); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Paravar, Taraneh, MD: UpToDate, Inc – O(H);
  • Schwarzenberger, Kathryn, MD: Pfizer Inc. – Data Safety Monitoring Board(Fees); Pretel, Inc. – F(NC);
  • Shinkai, Kanade, MD, PhD: no financial relationships exist with commercial interests.
  • Vleugels, Ruth Ann, MD: Pfizer Inc. – I(Fees);
Schedule
Sunday, March 3
1:00 PM
Dr. Callen / Introduction
1:05 PM
Dr. Micheletti / Case 1
1:23 PM
Dr. Vleugels / Case 2
1:41 PM
Dr. Kirsner / Case 3
1:59 PM
Dr. Shinkai / Case 4
2:17 PM
Dr. Owen / Case 5
2:35 PM
Dr. Paravar / Case 6
2:53 PM
Dr. Fett / Case 7
3:07 PM
Dr. Gudjonsson / Case 8
3:25 PM
Dr. Schwarzenberger / Case 9
3:41 PM
Dr. Maderal / Case 10
3:59 PM
Dr. Callen / Conclusion
Event Details
  • Date
    Sunday, March 3
  • Time
    1:00 PM - 4:00 PM
  • Location
    Ballroom C
  • CME Credits
    3.00
  • Type
    MOC
Directors/Co-Directors
  • Jeffrey Phillip Callen, MD, FAAD
Speakers
  • Andrea Maderal, MD, FAAD
  • Cindy Owen, MD, FAAD
  • Johann E. Gudjonsson, MD, FAAD
  • Kanade Shinkai, MD, PhD, FAAD
  • Kathryn Schwarzenberger, MD, FAAD
  • Nicole Fett, MD, FAAD
  • Robert Micheletti, MD, FAAD
  • Robert S. Kirsner, MD, PhD, FAAD
  • Ruth Ann Vleugels, MD, FAAD
  • Taraneh Paravar, MD, FAAD